Fenwick Represents OrsoBio in $60 Million Series A Financing

Fenwick represented OrsoBio, a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, in its $60 million Series A financing. The round was co-led by Longitude Capital and Enavate Sciences, with participation from Samsara BioCapital, NuevaBio and Eli Lilly and Company.

OrsoBio will use the funds to support the advancement of OrsoBio’s obesity-focused portfolio. More information can be obtained from the company’s announcement.

The Fenwick transaction team was led by corporate partner Bill Bromfield and included associates Leeza Soulina and Jing Liu.

Login

Don’t have an account yet?

Register